Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned favorably in the oncology market, with its product candidates NVL-520 and NVL-655 demonstrating deep and durable antitumor responses and improved tolerability, which may allow for a potential market expansion towards a projected peak revenue opportunity exceeding $3.6 billion. The company’s development of NVL-330, aimed at addressing HER2-driven tumors, is backed by encouraging preclinical data that suggest it could deliver durable responses in the central nervous system, further contributing to Nuvalent’s market potential. Additionally, the introduction of RNA-based NGS to enhance ROS1 detection rates and the favorable outlook for Nuvalent's ALK-inhibitor profile position the company to capture a significant share of the increasingly lucrative oncogene-driven non-small cell lung cancer market.

Bears say

Nuvalent Inc faces significant challenges that create a negative outlook for its stock, particularly regarding its clinical candidates' safety profiles and competitive positioning. Concerns over trial outcomes, potential regulatory hurdles, and the impact of adverse safety signals could hinder the advancement of its therapies, limiting market potential and commercialization timelines. Additionally, uncertainties related to trial enrollment, ongoing intellectual property risks, and the company's ability to secure necessary funding for research further exacerbate the company's precarious financial standing.

Nuvalent (NUVL) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 15 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.